Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial
(2005) In Journal of the National Cancer Institute 97(21). p.1609-1610- Abstract
- From January 1, 1983, through December 31, 1992, a total of 4610 patients entered a randomized trial that compared mortality among patients receiving 2 years of adjuvant tamoxifen therapy with that in patients receiving 5 years of adjuvant tamoxifen therapy, 4175 of whom were recurrence free after 2 years of tamoxifen therapy. Among the 2046 patients randomly assigned to the 5-year group all-cause mortality, breast cancer-specific mortality, and the incidence of contralateral breast cancer were reduced, compared with those among 2129 patients randomized in the 2-year group, but the incidence of endometrial cancer was increased. In addition, mortality from coronary heart disease was statistically significantly reduced in the 5-year group,... (More)
- From January 1, 1983, through December 31, 1992, a total of 4610 patients entered a randomized trial that compared mortality among patients receiving 2 years of adjuvant tamoxifen therapy with that in patients receiving 5 years of adjuvant tamoxifen therapy, 4175 of whom were recurrence free after 2 years of tamoxifen therapy. Among the 2046 patients randomly assigned to the 5-year group all-cause mortality, breast cancer-specific mortality, and the incidence of contralateral breast cancer were reduced, compared with those among 2129 patients randomized in the 2-year group, but the incidence of endometrial cancer was increased. In addition, mortality from coronary heart disease was statistically significantly reduced in the 5-year group, compared with that in the 2-year group (hazard ratio = 0.67, 95% confidence interval = 0.47 to 0.94; P = .022 [two-sided Wald test]). Ten years after surgery, 2.1% of the patients in the 5-year group and 3.5% of those in the 2-year group a died from coronary heart disease. No statistically significant increases in mortality from other heart diseases, cerebrovascular diseases, or other vascular diseases were observed. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/213816
- author
- Nordenskjold, B ; Rosell, J ; Rutqvist, L E ; Malmström, Per LU ; Bergh, J ; Bengtsson, N O ; Hatschek, T ; Wallgren, A and Carstensen, J
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of the National Cancer Institute
- volume
- 97
- issue
- 21
- pages
- 1609 - 1610
- publisher
- Oxford University Press
- external identifiers
-
- wos:000233117600012
- pmid:16264181
- scopus:27944460410
- pmid:16264181
- ISSN
- 1460-2105
- DOI
- 10.1093/jnci/dji342
- language
- English
- LU publication?
- yes
- id
- 798c4479-eeca-40ab-ba17-a3c5cfbff08a (old id 213816)
- date added to LUP
- 2016-04-01 15:59:16
- date last changed
- 2022-04-15 01:22:39
@article{798c4479-eeca-40ab-ba17-a3c5cfbff08a,
abstract = {{From January 1, 1983, through December 31, 1992, a total of 4610 patients entered a randomized trial that compared mortality among patients receiving 2 years of adjuvant tamoxifen therapy with that in patients receiving 5 years of adjuvant tamoxifen therapy, 4175 of whom were recurrence free after 2 years of tamoxifen therapy. Among the 2046 patients randomly assigned to the 5-year group all-cause mortality, breast cancer-specific mortality, and the incidence of contralateral breast cancer were reduced, compared with those among 2129 patients randomized in the 2-year group, but the incidence of endometrial cancer was increased. In addition, mortality from coronary heart disease was statistically significantly reduced in the 5-year group, compared with that in the 2-year group (hazard ratio = 0.67, 95% confidence interval = 0.47 to 0.94; P = .022 [two-sided Wald test]). Ten years after surgery, 2.1% of the patients in the 5-year group and 3.5% of those in the 2-year group a died from coronary heart disease. No statistically significant increases in mortality from other heart diseases, cerebrovascular diseases, or other vascular diseases were observed.}},
author = {{Nordenskjold, B and Rosell, J and Rutqvist, L E and Malmström, Per and Bergh, J and Bengtsson, N O and Hatschek, T and Wallgren, A and Carstensen, J}},
issn = {{1460-2105}},
language = {{eng}},
number = {{21}},
pages = {{1609--1610}},
publisher = {{Oxford University Press}},
series = {{Journal of the National Cancer Institute}},
title = {{Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial}},
url = {{http://dx.doi.org/10.1093/jnci/dji342}},
doi = {{10.1093/jnci/dji342}},
volume = {{97}},
year = {{2005}},
}